USFDA issues Form 483 with 8 observations to Jubilant

Jubilant Pharmova Limited is also involved in the manufacturing of active pharmaceutical ingredients (API) from its USFDA-approved facility in Nanjangud, India.

1250
USFDA Form 483
USFDA Form 483

Last Updated on October 2, 2024 by The Health Master

Noida: Jubilant Pharmova Limited has recently announced that the United States Food and Drug Administration (USFDA) has issued Form 483 with eight observations pursuant to the completion of the inspection at the company’s API manufacturing facility in Nanjangud, India.

The inspection was concluded on December 13, 2022.

“The company will submit an action plan on the observations and will engage with the USFDA for the next steps,” the company stated in a BSE filing.

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in specialty pharmaceuticals, contract research, development, and manufacturing (CRDMO), generics, and proprietary novel drug businesses.

Specialty pharmaceuticals, CDMOs, and generics businesses through Jubilant Pharma Limited Singapore (JPL) are engaged in the manufacturing and supply of radiopharmaceuticals with a network of radiopharmacies in the US.

Allergy Immunotherapy, contract manufacturing of sterile injectables and non-sterile products, and generic and branded formulations through five manufacturing facilities that cater to all the regulated markets, including the USA, Europe, and other geographies.

Jubilant Pharmova Limited is also involved in the manufacturing of active pharmaceutical ingredients (API) from its USFDA-approved facility in Nanjangud, India.

USFDA issues Form 483 with 8 observations to Lupin

USFDA issues Form 483 with 10 observations to Aurobindo Pharma

USFDA issues Form 483 with 3 Observations to Alkem

USFDA issues Form 483 with 5 observations to Lupin

USFDA issues Form 483 with one Observation to Laurus Labs

USFDA issues form 483 with 17 observations to Lupin

NPPA releases 5th list of draft ceiling prices for 69 formulations

DCOIWA to conduct workshops on Drugs & Medical Devices

US Court dismisses cancer linkage associated with Ranitidine

USFDA approves this lung cancer drug

International drug racket busted in Hyderabad, two held

Drug alert: 83 out of 1487 samples declared as NSQ in November 20222

FDA: Patients cannot be forced to buy medicines from hospital-attached pharmacies

Pharmacy education needs to adopt 2D, 3D format for lectures

Indian Pharma Companies have potential in Saudi Arabia

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news